Ayr Wellness Inc. (AYRWF)
(Delayed Data from OTC)
$2.77 USD
-0.64 (-18.77%)
Updated May 1, 2024 01:18 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
Ayr Wellness Inc. (AYRWF) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.67 | $5.00 | $2.52 | 7.62% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Ayr Wellness Inc. comes to $3.67. The forecasts range from a low of $2.52 to a high of $5.00. The average price target represents an increase of 7.62% from the last closing price of $3.41.
Analyst Price Targets (3 )
Broker Rating
Ayr Wellness Inc. currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 25% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/14/2024 | Roth Capital Partners | Scott Fortune | Strong Buy | Strong Buy |
3/1/2024 | Seaport Research Partners | Sonny Randhawa | Strong Buy | Strong Buy |
2/8/2024 | Needham & Company | Matthew R Mcginley | Hold | Hold |
11/17/2023 | Canaccord Genuity | Matt Bottomley | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 4 |
Average Target Price | $3.67 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 157 of 252 |
Current Quarter EPS Est: | -0.17 |